| Literature DB >> 27325104 |
Abner Louissaint1, Kristian T Schafernak2, Julia T Geyer3, Alexandra E Kovach4, Mahmoud Ghandi5, Dita Gratzinger6, Christine G Roth7, Christian N Paxton8, Sunhee Kim9, Chungdak Namgyal10, Ryan Morin11, Elizabeth A Morgan10, Donna S Neuberg12, Sarah T South13, Marian H Harris4, Robert P Hasserjian14, Ephraim P Hochberg15, Levi A Garraway16, Nancy Lee Harris14, David M Weinstock16.
Abstract
Pediatric-type nodal follicular lymphoma (PTNFL) is a variant of follicular lymphoma (FL) characterized by limited-stage presentation and invariably benign behavior despite often high-grade histological appearance. It is important to distinguish PTNFL from typical FL in order to avoid unnecessary treatment; however, this distinction relies solely on clinical and pathological criteria, which may be variably applied. To define the genetic landscape of PTNFL, we performed copy number analysis and exome and/or targeted sequencing of 26 PTNFLs (16 pediatric and 10 adult). The most commonly mutated gene in PTNFL was MAP2K1, encoding MEK1, with a mutation frequency of 43%. All MAP2K1 mutations were activating missense mutations localized to exons 2 and 3, which encode negative regulatory and catalytic domains, respectively. Missense mutations in MAPK1 (2/22) and RRAS (1/22) were identified in cases that lacked MAP2K1 mutations. The second most commonly mutated gene in PTNFL was TNFRSF14, with a mutation frequency of 29%, similar to that seen in limited-stage typical FL (P = .35). PTNFL was otherwise genomically bland and specifically lacked recurrent mutations in epigenetic modifiers (eg, CREBBP, KMT2D). Copy number aberrations affected a mean of only 0.5% of PTNFL genomes, compared with 10% of limited-stage typical FL genomes (P < .02). Importantly, the mutational profiles of PTNFLs in children and adults were highly similar. Together, these findings define PTNFL as a biologically and clinically distinct indolent lymphoma of children and adults characterized by a high prevalence of MAPK pathway mutations and a near absence of mutations in epigenetic modifiers.Entities:
Mesh:
Year: 2016 PMID: 27325104 PMCID: PMC5000844 DOI: 10.1182/blood-2015-12-682591
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113